FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209920981> ?p ?o ?g. }

• W3209920981 endingPage "S359" @default.
• W3209920981 startingPage "S359" @default.
• W3209920981 abstract "Introduction: Upadacitinib (UPA) is an oral, selective JAK inhibitor investigated for treatment of several immune-mediated inflammatory diseases, including ulcerative colitis (UC). Safety and efficacy of UPA in patients (pts) with moderately to severely active UC were studied in the phase 3 induction trials, U-ACHIEVE (NCT02819635) and U-ACCOMPLISH (NCT03653026). We assessed early (week 2) symptomatic improvement and decrease in biomarkers of inflammation during induction therapy with UPA 45 mg once daily (QC) compared with placebo (PBO). Methods: In the multicentre, double-blind, PBO-controlled U-ACHIEVE and U-ACCOMPLISH trials, pts with moderately to severely active UC were randomized 2:1 to UPA 45 mg QD or PBO for 8 weeks. This analysis evaluated the proportions of pts with clinical remission (per partial Mayo score), clinical response (per partial Mayo score), stool frequency subscore (SFS) ≤1, and rectal bleeding subscore (RBS) of 0, as well as change from baseline in fecal calprotectin and high-sensitivity C-reactive protein (hsCRP) at week 2 with UPA vs PBO. Statistical comparison between the two groups was performed according to the Cochran-Mantel-Haenszel test adjusted for baseline corticosteroid use (yes or no), baseline Adapted Mayo score (≤7 or >7), according to prior biologic response (bio-IR, biologic inadequate response/bio failure; non-bio-IR, nonbiologic inadequate response/non-bio-failure). Results: As early as week 2, a significantly higher proportion of pts who received UPA achieved clinical remission per partial Mayo score (23%) compared with PBO (5%; treatment difference, [95% CI]: 17.4 [11.8, 23.1]; P < 0.001) in U-ACHIEVE. Results were similar in U-ACCOMPLISH at week 2: UPA (31%) versus PBO (3%); treatment difference (95% CI): 26.5 (20.9, 32.1; P < 0.001). Similarly, higher proportions of pts receiving UPA 45 mg QD achieved other efficacy endpoints, including clinical response, SFS ≤1 and RBS = 0, at week 2 vs PBO (Table 1). Significant decreases from baseline in markers of inflammation (fecal calprotectin and hsCRP levels) were also observed with UPA vs PBO in both trials (Table 1). Safety was comparable with the known safety profile of UPA, and no new safety signals were identified. Conclusion: UPA 45 mg QD achieved rapid improvement in both symptomatic and objective biomarker measures as early as week 2 compared with PBO in pts with moderately to severely active UC. The results demonstrate rapid onset of treatment effect with UPA.Table 1.: Baseline Clinical Characteristics of Patients with Perianal Crohn's Disease" @default.
• W3209920981 created "2021-11-08" @default.
• W3209920981 creator A5008149243 @default.
• W3209920981 creator A5014242797 @default.
• W3209920981 creator A5022899630 @default.
• W3209920981 creator A5047563454 @default.
• W3209920981 creator A5056735741 @default.
• W3209920981 creator A5057854630 @default.
• W3209920981 creator A5058417911 @default.
• W3209920981 creator A5081674539 @default.
• W3209920981 creator A5084914098 @default.
• W3209920981 creator A5090598423 @default.
• W3209920981 date "2021-10-01" @default.
• W3209920981 modified "2023-10-16" @default.
• W3209920981 title "S773 Rapidity of Symptom Control with Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two Randomized Phase 3 Studies" @default.
• W3209920981 doi "https://doi.org/10.14309/01.ajg.0000776624.73243.66" @default.
• W3209920981 hasPublicationYear "2021" @default.
• W3209920981 type Work @default.
• W3209920981 sameAs 3209920981 @default.
• W3209920981 citedByCount "0" @default.
• W3209920981 crossrefType "journal-article" @default.
• W3209920981 hasAuthorship W3209920981A5008149243 @default.
• W3209920981 hasAuthorship W3209920981A5014242797 @default.
• W3209920981 hasAuthorship W3209920981A5022899630 @default.
• W3209920981 hasAuthorship W3209920981A5047563454 @default.
• W3209920981 hasAuthorship W3209920981A5056735741 @default.
• W3209920981 hasAuthorship W3209920981A5057854630 @default.
• W3209920981 hasAuthorship W3209920981A5058417911 @default.
• W3209920981 hasAuthorship W3209920981A5081674539 @default.
• W3209920981 hasAuthorship W3209920981A5084914098 @default.
• W3209920981 hasAuthorship W3209920981A5090598423 @default.
• W3209920981 hasBestOaLocation W32099209811 @default.
• W3209920981 hasConcept C126322002 @default.
• W3209920981 hasConcept C142724271 @default.
• W3209920981 hasConcept C168563851 @default.
• W3209920981 hasConcept C204787440 @default.
• W3209920981 hasConcept C27081682 @default.
• W3209920981 hasConcept C2778260677 @default.
• W3209920981 hasConcept C2778292693 @default.
• W3209920981 hasConcept C2779134260 @default.
• W3209920981 hasConcept C2780479503 @default.
• W3209920981 hasConcept C535046627 @default.
• W3209920981 hasConcept C71924100 @default.
• W3209920981 hasConcept C90924648 @default.
• W3209920981 hasConceptScore W3209920981C126322002 @default.
• W3209920981 hasConceptScore W3209920981C142724271 @default.
• W3209920981 hasConceptScore W3209920981C168563851 @default.
• W3209920981 hasConceptScore W3209920981C204787440 @default.
• W3209920981 hasConceptScore W3209920981C27081682 @default.
• W3209920981 hasConceptScore W3209920981C2778260677 @default.
• W3209920981 hasConceptScore W3209920981C2778292693 @default.
• W3209920981 hasConceptScore W3209920981C2779134260 @default.
• W3209920981 hasConceptScore W3209920981C2780479503 @default.
• W3209920981 hasConceptScore W3209920981C535046627 @default.
• W3209920981 hasConceptScore W3209920981C71924100 @default.
• W3209920981 hasConceptScore W3209920981C90924648 @default.
• W3209920981 hasIssue "1" @default.
• W3209920981 hasLocation W32099209811 @default.
• W3209920981 hasLocation W32099209812 @default.
• W3209920981 hasOpenAccess W3209920981 @default.
• W3209920981 hasPrimaryLocation W32099209811 @default.
• W3209920981 hasRelatedWork W1607640586 @default.
• W3209920981 hasRelatedWork W2037617951 @default.
• W3209920981 hasRelatedWork W2090228779 @default.
• W3209920981 hasRelatedWork W2091592849 @default.
• W3209920981 hasRelatedWork W2102588492 @default.
• W3209920981 hasRelatedWork W2140869523 @default.
• W3209920981 hasRelatedWork W2316463897 @default.
• W3209920981 hasRelatedWork W2356562650 @default.
• W3209920981 hasRelatedWork W2805263272 @default.
• W3209920981 hasRelatedWork W2997655348 @default.
• W3209920981 hasVolume "116" @default.
• W3209920981 isParatext "false" @default.
• W3209920981 isRetracted "false" @default.
• W3209920981 magId "3209920981" @default.
• W3209920981 workType "article" @default.